GlassScriptPhysician profile
James Trippett
NPI 1366473894
$17,648.35
in general payments reported to CMS, 2019-2025
69 companies · $3,117 in 2025
The $3,117 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,339 · 2020: $1,952 · 2021: $2,440 · 2022: $2,409 · 2023: $2,486 · 2024: $2,905 · 2025: $3,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,492 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,491.54 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,039.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $1,730.86 | 2021-2025 | Freestyle Libre 3, Eterna, Prodigy |
| Amgen INC. | $1,255.24 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $1,113.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,045.20 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $902.06 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $864.25 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Optinose US, INC. | $656.55 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $627.54 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $587.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $547.84 | 2019-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Pfizer INC. | $511.75 | 2019-2025 | |
| Amarin Pharma, INC. | $489.43 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $444.95 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $398.02 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Trippett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.